An IgE receptor mimetic peptide (PepE) protects mice from IgE mediated anaphylaxis

An IgE receptor mimetic peptide (PepE) protects mice from IgE mediated anaphylaxis (332 visite)

Zhou JS, Sandomenico A, Burton O, Oettgen HC, Ruvo M

Molecular Biosystems (ISSN: 1742-206x), 2013 Nov; 9(11): 2853-2859.

Tipo di articolo: Journal Article, Research Support, N. I. H. , Extramural, Non-U. S. Gov'T,

Impact factor: 3.183, Impact factor a 5 anni: 3.359

Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84885168763&partnerID=40&md5=2e0b01eae4f473d06f408c187fde5a2f

Parole chiave: Immunoglobulin E, Immunoglobulin E Receptor, Peptide, Protein Binding, Amino Acid Sequence, Anaphylaxis, Animal, Chemistry, Disease Model, Female, Genetics, Immunology, Knockout Mouse, Metabolism, Molecular Mimicry, Article, Time Factors, Anaphylaxis Genetics Immunology Prevention, Control, Immunoglobulin E Genetics Immunology Metabolism, Peptides Administration, Dosage Chemistry Pharmacology, Protein Binding Immunology, Ige Chemistry,

Affiliazioni:

*** IBB - CNR ***
Boston Children's Hospital, Boston MA 02115, United States
Boston Medical Center, Boston University School of Medicine, Boston MA 02118, United States
Istituto di Biostrutture e Bioimmagini, CNR, Centro Interuniversitario di Ricerca sui Peptidi Bioattivi (CIRPeB), via Mezzocannone 16, I-80134 Naples, Italy
Seconda Università di Napoli, via Vivaldi 43, Caserta Napoli, Italy
Seconda Universit di Napoli, via Vivaldi 43, Caserta Napoli, Italy

Riferimenti:

Burton, O.T., Oettgen, H.C., (2011) Immunol. Rev., 242, pp. 128-14

Galli, S.J.T., Tsai, M., (2012) Nat. Med., 18, pp. 693-704

Kraft, S., Kinet, J.P., (2007) Nat. Rev. Immunol., 7, pp. 365-378

Lieberman, J.A., Chehade, M., (2013) Curr. Allergy Asthma Rep., 13, pp. 78-84

Fried, A.J., Oettgen, H.C., (2010) Curr. Opin. Pediatr., 22, pp. 758-764

Wastling, J.M., Scudamore, C.L., Thornton, E.M., Newlands, G.F., Miller, H.R., (1997) Immunology, 90, pp. 308-313

Helm, B., Kebo, D., Vercelli, D., Glovsky, M.M., Gould, H., Ishizaka, K., Geha, R., Ishizaka, T., (1989) Proc. Natl. Acad. Sci. U. S. A., 86, pp. 9465-9469

Rigby, L.J., Trist, H., Snider, J., Hulett, M.D., Hogarth, P.M., Epa, V.C., (2000) Allergy, 55, pp. 609-619

Stamos, J., Eigenbrot, C., Nakamura, G.R., Reynolds, M.E., Yin, J., Lowman, H.B., Fairbrother, W.J., Starovasnik, M.A., (2004) Structure, 12, pp. 1289-1301

Buku, A., Keselman, I., Lupyan, D., Mezei, M., Price, J.A., (2008) Chem. Biol. Drug Des., 72, pp. 133-139

Buku, A., Price, J.A., Mendlowitz, M., Masur, S., (2001) Peptides, 22, pp. 1993-1998

Nakamura, G.R., Starovasnik, M.A., Reynolds, M.E., Lowman, H.B., (2001) Biochemistry, 40, pp. 9828-9835

Sandomenico, A., Monti, S.M., Marasco, D., Dathan, N., Palumbo, R., Saviano, M., Ruvo, M., (2009) Mol. Immunol., 46, pp. 3300-3309

Mathias, C.B., Hobson, S.A., Garcia-Lloret, M., Lawson, G., Poddighe, D., Freyschmidt, E.J., Xing, W., Oettgen, H.C., (2011) J. Allergy Clin. Immunol., 127, pp. 795-805. , e791-e796

Fields, G.B., Noble, R.L., (1990) Int. J. Pept. Protein Res., 35, pp. 161-214

Oettgen, H.C., Martin, T.R., Wynshaw-Boris, A., Deng, C., Drazen, J.M., Leder, P., (1994) Nature, 370, pp. 367-370

Hayashi, N., Tsukamoto, Y., Sallas, W.M., Lowe, P.J., (2007) Br. J. Clin. Pharmacol., 63, pp. 548-561

Bedoret, D., Singh, A.K., Shaw, V., Hoyte, E.G., Hamilton, R., Dekruyff, R.H., Schneider, L.C., Umetsu, D.T., (2012) Mucosal Immunol., 5, pp. 267-276

Crosslinking of receptor-bound Immunoglobulin E (IgE) triggers immediate hypersensitivity reactions including anaphylaxis. Blocking the interaction of IgE with its high-affinity receptor, FceRI, on mast cells and basophils is an attractive strategy for the treatment of allergies. This approach has seen clinical success using the anti-IgE monoclonal antibody, omalizumab. We recently designed and characterized a novel FceRI-mimetic peptide (PepE) which contains the two key FceRI alpha-chain receptor loops known to interact with the e-heavy chain of IgE, C'-E and B-C, with an optimized linker for joining them. PepE has high specificity and affinity for IgE, blocks IgE binding to FceRI and prevents IgE-induced mediator release from RBL2H3 cells. We have now investigated the biological effects of this peptide in vivo using a line of mice (BALB/c Il4raF709) very sensitive to IgE-mediated systemic anaphylaxis. IgE-deficient (IgE(-/-)) Il4raF709 mice were passively sensitized with the anti-DNP IgE monoclonal antibody (SPE-7) and subsequently challenged i. v. with DNP-BSA. Mice receiving a single dose of PepE prior to sensitization with SPE-7 IgE were fully protected from anaphylaxis while vehicle control-treated mice displayed strong reactions with significant core body temperature drops and elevated levels of mouse mast cell protease-1 (mMCP-1) in the serum. However, PepE had no effect on IgE-mediated anaphylaxis if given after IgE administration in IgE(-/-) mice, suggesting that PepE can block binding of free IgE to FceRI but cannot compete with the receptor for already bound IgE in vivo. A single dose of PepE treatment did not protect IgE sufficient mice from IgE mediated anaphylaxis. However, a 3 week long course of PepE treatment protected IgE sufficient Il4raF709 mice from body temperature drops and elevation of serum mMCP-1. Our findings establish the potential of this type of structure for blocking IgE binding to mast cells in vivo and suggest that related peptides might have the potential to attenuate clinical allergic reactions.